核因子赤血球2関連因子2治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0883
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:145
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Nuclear Factor Erythroid 2 Related Factor 2 – Pipeline Review, H1 2020
Summary

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 39 molecules. Out of which approximately 33 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 5, 20 and 1 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Musculoskeletal Disorders, Ophthalmology, Respiratory, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease and Toxicology which include indications Multiple Sclerosis, Psoriasis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Systemic Sclerosis (Scleroderma), Chronic Kidney Disease (Chronic Renal Failure), Friedreich Ataxia, Huntington Disease, Mitochondrial Myopathy, Non-Alcoholic Steatohepatitis (NASH), Osteoarthritis, Relapsing Remitting Multiple Sclerosis (RRMS), Retinal Degeneration, Type 2 Diabetes, Acne Vulgaris, Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), Age Related Macular Degeneration, Alport Syndrome, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Asbestosis, Aspiration Pneumonitis, Asthma, Atherosclerosis, Breast Cancer, Bullous Pemphigoid, Cardiomyopathy, Cerebral Vasospasm, Chagas Disease (American Trypanosomiasis), Diabetic Complications, Diffuse Large B-Cell Lymphoma, Duchenne Muscular Dystrophy, Encephalomyelitis, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, IgA Nephropathy (Berger’s Disease), Inflammation, Ischemia Reperfusion Injury, Ischemic Stroke, Keloids, Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Lung Injury, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Osteoporosis, Ovarian Cancer, Parkinson’s Disease, Pervasive Developmental Disorder (PDD), Plaque Psoriasis (Psoriasis Vulgaris), Polycystic Kidney Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pulmonary Hypertension, Radiodermatitis, Refractory Medulloblastoma, Retinopathy, Sickle Cell Disease, Spinocerebellar Ataxia (SCA), Subacute Necrotizing Encephalomyelopathy (Leigh Disease), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

The latest report Nuclear Factor Erythroid 2 Related Factor 2 – Pipeline Review, H1 2020, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
Introduction
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Overview
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Therapeutics Development
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Therapeutics Assessment
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Companies Involved in Therapeutics Development
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Drug Profiles
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Dormant Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Discontinued Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AKL Research and Development Ltd, H1 2020
Pipeline by Allianz Pharmascience Ltd, H1 2020
Pipeline by Arbor Pharmaceuticals LLC, H1 2020
Pipeline by Bach Pharma Inc, H1 2020
Pipeline by Bayer AG, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Discontinued Products, H1 2020

【掲載企業】

AKL Research and Development Ltd
Allianz Pharmascience Ltd
Arbor Pharmaceuticals LLC
Bach Pharma Inc
Bayer AG
BioApex sro
Biogen Inc
C4X Discovery Holdings Plc
Cureveda LLC
Daiichi Sankyo Co Ltd
Evgen Pharma Plc
Immungenetics AG
Ixchel Pharma LLC
Jiangsu Hengrui Medicine Co Ltd
Lignamed LLC
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rescue Therapeutics Inc
Scohia Pharma Inc
Sulfateq BV
V Clinbio LLC
Vitalis LLC
vTv Therapeutics Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[核因子赤血球2関連因子2治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆